New immune booster shows promise in early breast cancer trial
NCT ID NCT02950259
First seen Jan 03, 2026 · Last updated Jun 17, 2026 · Updated 25 times
Summary
This study tested a new immune-boosting treatment called IRX-2 in 16 people with early stage breast cancer. The goal was to see if giving IRX-2 before chemotherapy is safe and helps the immune system fight the tumor. The treatment was given before surgery, and researchers looked for any delays in surgery and changes in immune cells inside the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.